REPORT 156
Doxycycline 100 mg tablets for Donovanosis treatment

Ordinance n° 55/2015 published on 10/05/2015
EXECUTIVE SUMMARY

**Technology:** Doxycycline 100 mg (tablet).

**Indication:** Donovanosis treatment.

**Applicant:** Secretariat of Health Surveillance – SVS.

**Context:** Donovanosis is a progressive and chronic disease frequently associated with sexual transmission, caused by the bacterium Klebsiella granulomatis, and affects mainly skin and mucous membranes of the genital, perianal and inguinal regions. It is infrequent, with an incidence of approximately 5% among STDs. Doxycycline is one of the drugs recommended by the Ministry of Health for the treatment of donovanosis, but the drug is not yet available in SUS for this indication.

**Budget Impact:** In order to assess the budget impact of extending the use of doxycycline 100 mg for the treatment of donovanosis, its treatment cost was compared to the treatment costs for the drugs recommended by the Ministry of Health for the same indication and incorporated into SUS: erythromycin estolate 500 mg, sulfamethoxazole+trimethoprim 800+160 mg, tetracycline 500 mg and azithromycin 500 mg. The treatment cost with doxycycline was lower than the treatment costs with all the other drugs.

**Final Deliberation:** CONITEC members unanimously deliberated in favor of recommending the incorporation of doxycycline 100 mg for donovanosis treatment.

**Decision:** To incorporate doxycycline 100 mg tablets for donovanosis treatment, as per the technical regulations defined by the Ministry of Health, within the scope of Sistema Único de Saúde-SUS. Ordinance nº 55, published in DOU nº 190, page 692, dated 10/05/2015.